Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Randomised data will be needed to answer lingering questions about DKN-01.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.